{"id":"NCT00424463","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","officialTitle":"An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2007-01-19","resultsPosted":"2018-06-04","lastUpdate":"2018-08-23"},"enrollment":181,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"interventions":[{"type":"DRUG","name":"MCI-186","otherNames":["Edaravone","Radicut"]},{"type":"DRUG","name":"Placebo of MCI-186","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel assignment, 24-week study in the treatment of ALS. The objectives of this study are to assess the efficacy and safety of long-term intermittent therapy with 60 mg MCI-186 to ALS patients.","primaryOutcome":{"measure":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","timeFrame":"baseline (seventh cycle) and at 24 week (twelfth cycle)","effectByArm":[{"arm":"MCI-186 - Placebo of MCI-186","deltaMin":-5.5,"sd":4.6},{"arm":"MCI-186 - MCI-186","deltaMin":-4.2,"sd":4},{"arm":"Placebo of MCI-186 - MCI-186","deltaMin":-5.4,"sd":4.5}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["28872918","28872914"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":45},"commonTop":["Nasopharyngitis","Gait disturbance","Constipation","Contusion","Insomnia"]}}